|
시장보고서
상품코드
2024679
인공 췌장 디바이스 시스템 시장 보고서 : 디바이스 유형별, 치료 유형별, 최종사용자별, 지역별(2026-2034년)Artificial Pancreas Device Systems Market Report by Device Type, Treatment Type, End-User, and Region 2026-2034 |
||||||
세계의 인공 췌장 디바이스 시스템(APDS) 시장 규모는 2025년에 28억 3,450만 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 63억 5,990만 달러에 달하며, 2026-2034년에 CAGR 9.11%로 성장할 것으로 예측하고 있습니다.
APDS는 인슐린 분비를 조절하여 혈당을 관리하는 폐쇄형 또는 자동 인슐린 투여 시스템을 말합니다. 지속적 혈당 모니터(CGM), 피하 인슐린 주입 펌프, 그리고 모니터와 펌프를 연결하는 컨트롤러로 구성됩니다. 이 시스템은 실시간 혈당 측정 결과를 평가하고 적절한 인슐린 용량과 투여 시기를 결정하는 복잡한 알고리즘을 실행합니다. 이는 주로 체내 혈당 수치가 극단적으로 변동하는 위험을 최소화하기 위해 사용됩니다.
췌장암, 췌장염 및 기타 만성질환의 유병률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한 고령화, 운동 부족, 건강에 해로운 식습관으로 인한 당뇨병과 비만의 증가도 APDS가 전 세계에서 널리 채택되는 요인으로 작용하고 있습니다. 효율적인 당뇨병 모니터링 및 최소침습(MI) 약물전달 시스템에 대한 수요 증가도 시장 성장을 촉진하고 있습니다. APDS는 혈당 수치를 자동으로 모니터링하여 하루 종일 조절된 양의 인슐린을 투여합니다. 자동 제어 및 통합 소프트웨어 기반 무선 시스템 개발을 포함한 다양한 기술 혁신이 시장 성장을 더욱 촉진하고 있습니다. 또한 각국의 규제 당국과 정부는 전 세계 의료 인프라 개선을 위한 연구개발(R&D)에 많은 투자를 하고 있습니다. 예를 들어 미국 식품의약국(FDA)은 새롭고 혁신적인 제품의 승인 건수를 늘리고 있으며, 이는 미국 시장의 전망을 밝게 하고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 인공 췌장 디바이스 시스템 시장
제6장 시장 내역 : 디바이스 유형별
제7장 시장 내역 : 치료 유형별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porters Five Forces 분석
제13장 가격 지표
제14장 경쟁 구도
KSA 26.05.18The global artificial pancreas device systems (APDS) market size reached USD 2,834.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 6,359.9 Million by 2034, exhibiting a growth rate (CAGR) of 9.11% during 2026-2034.
APDS refers to a closed-loop or automated insulin delivery system that manages blood glucose levels by regulating the production of insulin. It consists of a continuous glucose monitor (CGM), a subcutaneous insulin infusion pump and a controller that links the monitor with the pump. It runs a complex algorithm that determines the adequate levels of insulin and time of delivery based on the evaluation of real-time glucose readings. It is primarily used to minimize the risks of extreme fluctuations of glucose levels in the body.
The increasing prevalence of pancreatic cancer, pancreatitis and other chronic ailments is one of the key factors driving the growth of the market. Furthermore, the growing occurrence of diabetes and obesity, due to age-related factors, physical inactivity and unhealthy dietary patterns, is also contributing to the widespread adoption of APDS across the globe. The rising demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also providing a boost to the market growth. APDS automatically monitors the glucose levels and administers doses of insulin throughout the day in controlled amounts. Various technological innovations, including the development of software-based wireless systems that are integrated with automated controls, are further contributing to the market growth. Moreover, regulatory bodies and governments of various nations are significantly investing in research and development (R&D) for the improvement of healthcare infrastructure across the globe. For instance, the Food and Drug Association (US FDA) in the United States is approving an increasing number of new and innovative products, which is creating a positive outlook for the market in the country.
KEY MARKET SEGMENTATION :
Breakup by Device Type:
- Threshold Suspend Device Systems
- Control-to-Range Systems
- Control-to-Target Systems
Breakup by Treatment Type:
- Bi-hormonal
- Insulin Only
- Hybrid
Breakup by End-User:
- Hospitals
- Medical Centres
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The report provides a comprehensive analysis of the competitive landscape in the global artificial pancreas device systems (APDS) market with detailed profiles of all major companies, including:
- Beta Bionics, Inc.
- Bigfoot Biomedical Inc.
- Diabeloop
- Insulet Corporation
- Medtronic Plc
- Tandem Diabetes Care, Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global artificial pancreas device systems market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global artificial pancreas device systems market?
- What is the breakup of the market based on the device type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global artificial pancreas device systems market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Artificial Pancreas Device Systems Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Device Type
- 6.1 Threshold Suspend Device Systems
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Control-to-Range Systems
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Control-to-Target Systems
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Treatment Type
- 7.1 Bi-hormonal
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Insulin Only
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Hybrid
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by End-User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Medical Centres
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Indicators
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Beta Bionics, Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Bigfoot Biomedical Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Diabeloop
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Insulet Corporation
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.5 Medtronic Plc
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Tandem Diabetes Care, Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.1 Beta Bionics, Inc.
